JPMorgan upgraded Recursion Pharmaceuticals (RXRX) to Overweight from Neutral with a price target of $11, up from $10. The firm says the company’s REC-4881 has shown “strong and durable” efficacy in ...

Copyright © 2025 Insider Inc and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Magnesis is going to be your friend for the rest of this trial. Drag the cubes out of the area you unlocked, and then turn to the scale at the one end of the room, you will see a chest in one upper ...